These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy. English BC; Price DK; Figg WD Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467 [No Abstract] [Full Text] [Related]
3. Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab. Kim YH; Mishima M; Miyagawa-Hayashino A J Thorac Oncol; 2010 Jul; 5(7):1107-8. PubMed ID: 20581581 [No Abstract] [Full Text] [Related]
4. Bevacizumab for retinopathy of prematurity. Lim LS; Mitchell P; Wong TY N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897 [No Abstract] [Full Text] [Related]
5. Bevacizumab in the treatment of colorectal cancer. Cilley JC; Barfi K; Benson AB; Mulcahy MF Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810 [TBL] [Abstract][Full Text] [Related]
6. [Bevacizumab and radiotherapy]. Blanchard P; Besse B; Deutsch E Rev Mal Respir; 2008 Dec; 25(10):1319-21. PubMed ID: 19107021 [No Abstract] [Full Text] [Related]
7. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. El Maalouf G; Mitry E; Lacout A; Lièvre A; Rougier P J Neurol; 2008 Feb; 255(2):295-6. PubMed ID: 18283405 [No Abstract] [Full Text] [Related]
8. Targeted therapies: bevacizumab--has it reached its final resting place? Kerr DJ; Young AM Nat Rev Clin Oncol; 2011 Mar; 8(4):195-6. PubMed ID: 21386819 [No Abstract] [Full Text] [Related]
9. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Mautner VF; Nguyen R; Knecht R; Bokemeyer C Ann Oncol; 2010 Nov; 21(11):2294-2295. PubMed ID: 20860987 [No Abstract] [Full Text] [Related]
10. Debate on the various anti-vascular endothelial growth factor drugs. Khalili MR; Hosseini H Indian J Ophthalmol; 2008; 56(3):255-6; author reply 256. PubMed ID: 18417837 [No Abstract] [Full Text] [Related]
13. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles. Miles D Drugs; 2007; 67(12):1800-1. PubMed ID: 17683177 [No Abstract] [Full Text] [Related]
14. Bevacizumab for retinopathy of prematurity. Gilbert CE; Zin A; Darlow B N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898 [No Abstract] [Full Text] [Related]
15. Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed. González Martín A Clin Transl Oncol; 2009 Sep; 11(9):559-60. PubMed ID: 19775993 [No Abstract] [Full Text] [Related]
17. Anti-VEGF therapy in proliferative diabetic retinopathy. Abdallah W; Fawzi AA Int Ophthalmol Clin; 2009; 49(2):95-107. PubMed ID: 19349790 [No Abstract] [Full Text] [Related]
18. Bevacizumab and surgery: what is the real risk? Cohen R; Stebbing J; Windsor A Future Oncol; 2009 Sep; 5(7):915-7. PubMed ID: 19792957 [No Abstract] [Full Text] [Related]
19. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by Xavier Pivot. Pivot X Drugs; 2007; 67(12):1800-1. PubMed ID: 17683176 [No Abstract] [Full Text] [Related]